A Cancer and Leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Indoles
  • Pancreatic Neoplasms
  • Pyrroles
  • Salvage Therapy

abstract

  • The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients. For future studies, limiting enrollment to patients with an ECOG performance status score of 0-1 is recommended.

publication date

  • December 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3227926

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2010-0152

PubMed ID

  • 21148613

Additional Document Info

start page

  • 1310

end page

  • 9

volume

  • 15

number

  • 12